Tourmaline Bio (TRML) Plunges 7.37% After Truist Cuts Price Target

Mover TrackerThursday, Apr 10, 2025 6:28 pm ET
1min read

Tourmaline Bio (TRML) shares fell 3.01% today, reaching their lowest level since October 2023, with an intraday decline of 7.37%.

One of the primary factors influencing the stock price of

(TRML) is the recent adjustment of its price target by Truist. Truist lowered the price target from $74 to $63 while maintaining a Buy rating on the shares. This adjustment could influence investor perception and trading behavior, potentially impacting the stock price.

Comments



Add a public comment...
No comments

No comments yet

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.